Cargando…
Chloroquine/favipiravir/rituximab: COVID-19-pneumonia, off-label use and lack of efficacy: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732227/ http://dx.doi.org/10.1007/s40278-022-07862-0 |
Ejemplares similares
-
Favipiravir: Lack of efficacy following off-label treatment: case report
Publicado: (2021) -
Favipiravir/methylprednisolone: Off-label use and lack of efficacy: case report
Publicado: (2022) -
Favipiravir: Lack of efficacy secondary to off label use in COVID-19: Case report: case report
Publicado: (2021) -
Colchicine/favipiravir/prednisolone: Lack of efficacy and off label use: case report
Publicado: (2021) -
Azithromycin/favipiravir/hydroxychloroquine: Lack of efficacy and off-label use: case report
Publicado: (2021)